Literature DB >> 30875096

Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity.

Qi Zhao1,2, Ting Zhang1,2, Xue-Rong Xiao1, Jian-Feng Huang1,2, Yan Wang3, Frank J Gonzalez4, Fei Li1,5.   

Abstract

BACKGROUND AND
PURPOSE: Sunitinib is a small-molecule TK inhibitor associated with hepatotoxicity. The mechanisms of its toxicity are still unclear. EXPERIMENTAL APPROACH: In the present study, mice were treated with 60, 150, and 450 mg·kg-1 sunitinib to evaluate sunitinib hepatotoxicity. Sunitinib metabolites and endogenous metabolites in liver, serum, faeces, and urine were analysed using ultra-performance LC electrospray ionization quadrupole time-of-flight MS-based metabolomics. KEY
RESULTS: Four reactive metabolites and impaired clearance of sunitinib in liver played a dominant role in sunitinib-induced hepatotoxicity. Using a non-targeted metabolomics approach, various metabolic pathways, including mitochondrial fatty acid β-oxidation (β-FAO), bile acids, lipids, amino acids, nucleotides, and tricarboxylic acid cycle intermediates, were disrupted after sunitinib treatment. CONCLUSIONS AND IMPLICATIONS: These studies identified significant alterations in mitochondrial β-FAO and bile acid homeostasis. Activation of PPARα and inhibition of xenobiotic metabolism may be of value in attenuating sunitinib hepatotoxicity.
© 2019 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30875096      PMCID: PMC6555861          DOI: 10.1111/bph.14664

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  58 in total

1.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis.

Authors:  Kate M O'Brien; Katryn M Allen; Cheryl E Rockwell; Keara Towery; James P Luyendyk; Bryan L Copple
Journal:  Am J Pathol       Date:  2013-09-05       Impact factor: 4.307

Review 3.  Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors.

Authors:  Hajime Higuchi; Gregory J Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-05       Impact factor: 4.052

4.  Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.

Authors:  M H M Diekstra; H J Klümpen; M P J K Lolkema; H Yu; J S L Kloth; H Gelderblom; R H N van Schaik; H Gurney; J J Swen; A D R Huitema; N Steeghs; R H J Mathijssen
Journal:  Clin Pharmacol Ther       Date:  2014-02-24       Impact factor: 6.875

5.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters.

Authors:  Stephen Ph Alexander; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

6.  Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?

Authors:  Renato Tassi; Valentina Baldazzi; Alberto Lapini; Marco Carini; Roberto Mazzanti
Journal:  Clin Genitourin Cancer       Date:  2014-09-22       Impact factor: 2.872

7.  The metabolic interconversion of arecoline and arecoline 1-oxide in the rat.

Authors:  R Nery
Journal:  Biochem J       Date:  1971-05       Impact factor: 3.857

8.  Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis.

Authors:  Franziska Paech; Jamal Bouitbir; Stephan Krähenbühl
Journal:  Front Pharmacol       Date:  2017-06-14       Impact factor: 5.810

9.  PPARα activation protects against cholestatic liver injury.

Authors:  Qi Zhao; Rui Yang; Jing Wang; Dan-Dan Hu; Fei Li
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

10.  Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis.

Authors:  Brian C Jensen; Traci L Parry; Wei Huang; Ju Youn Beak; Amro Ilaiwy; James R Bain; Christopher B Newgard; Michael J Muehlbauer; Cam Patterson; Gary L Johnson; Monte S Willis
Journal:  Br J Pharmacol       Date:  2017-11-24       Impact factor: 8.739

View more
  9 in total

1.  Metabolic profiling of norepinephrine reuptake inhibitor atomoxetine.

Authors:  Kevin R MacKenzie; Mingkun Zhao; Mercedes Barzi; Jin Wang; Karl-Dimiter Bissig; Mirjana Maletic-Savatic; Sung Yun Jung; Feng Li
Journal:  Eur J Pharm Sci       Date:  2020-07-23       Impact factor: 4.384

Review 2.  Advances in the study of drug metabolism - symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX).

Authors:  Laura E Russell; Mary Alexandra Schleiff; Eric Gonzalez; Aaron G Bart; Fabio Broccatelli; Jessica H Hartman; W Griffith Humphreys; Volker M Lauschke; Iain Martin; Chukwunonso Nwabufo; Bhagwat Prasad; Emily E Scott; Matthew Segall; Ryan Takahashi; Mitchell E Taub; Jasleen K Sodhi
Journal:  Drug Metab Rev       Date:  2020-05-26       Impact factor: 4.518

3.  Role of Metabolic Activation in Elemicin-Induced Cellular Toxicity.

Authors:  Yi-Kun Wang; Xiao-Nan Yang; Xu Zhu; Xue-Rong Xiao; Xiu-Wei Yang; Hong-Bo Qin; Frank J Gonzalez; Fei Li
Journal:  J Agric Food Chem       Date:  2019-07-16       Impact factor: 5.279

4.  Impaired clearance of sunitinib leads to metabolic disorders and hepatotoxicity.

Authors:  Qi Zhao; Ting Zhang; Xue-Rong Xiao; Jian-Feng Huang; Yan Wang; Frank J Gonzalez; Fei Li
Journal:  Br J Pharmacol       Date:  2019-05-07       Impact factor: 8.739

5.  Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation.

Authors:  Elizabeth A Burnham; Arsany A Abouda; Jennifer E Bissada; Dasean T Nardone-White; Jessica L Beers; Jonghwa Lee; Matthew J Vergne; Klarissa D Jackson
Journal:  Chem Res Toxicol       Date:  2022-04-28       Impact factor: 3.973

Review 6.  Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.

Authors:  Ramón Cacabelos; Vinogran Naidoo; Lola Corzo; Natalia Cacabelos; Juan C Carril
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

Review 7.  Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature.

Authors:  Hana Studentova; Jindriska Volakova; Martina Spisarova; Anezka Zemankova; Kvetoslava Aiglova; Tomas Szotkowski; Bohuslav Melichar
Journal:  BMC Gastroenterol       Date:  2022-02-05       Impact factor: 3.067

8.  Polyamine metabolism links gut microbiota and testicular dysfunction.

Authors:  Qi Zhao; Jian-Feng Huang; Yan Cheng; Man-Yun Dai; Wei-Feng Zhu; Xiu-Wei Yang; Frank J Gonzalez; Fei Li
Journal:  Microbiome       Date:  2021-11-11       Impact factor: 14.650

9.  Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice.

Authors:  Xuan Qin; John M Hakenjos; Kevin R MacKenzie; Mercedes Barzi; Hemantkumar Chavan; Pranavanand Nyshadham; Jin Wang; Sung Yun Jung; Joie Z Guner; Si Chen; Lei Guo; Partha Krishnamurthy; Karl-Dimiter Bissig; Stephen Palmer; Martin M Matzuk; Feng Li
Journal:  Drug Metab Dispos       Date:  2021-11-16       Impact factor: 3.922

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.